Abstract:Background: Treating and managing heart failure with preserved ejection fraction (HFpEF) remains challenging. With the gradual increase in the number of obese individuals, diabetics, and cases of hypertension, HFpEF prevalence accounts for half of the total number of patients with heart failure. HFpEF, for which no specific treatment exists, is the most challenging problem. Objective: To investigate the cardioprotective effects and mechanisms of an adiponectin receptor agonist, AdipoRon, as an anti-inflammatory agent in a two-hit HFpEF mice model. Methods: A mouse model of HFpEF was induced using a 60% high-fat diet plus 5.0g/L L-NAME drinking water for 12 weeks. AdipoRon (50 mg/kg) or a comparable volume of saline via gavage once daily was administered to the two-hit HFpEF mice model for four weeks. Cardiac function was evaluated by echocardiography, while molecular biology techniques were employed to determine the effect of AdipoRon. Results: The oral adiponectin receptor agonist, AdipoRon, inhibited HFpEF inflammation by downregulating NLRP3, caspase-1, IL-1β and IL-18, and suppressing the TLR4/NF-κB/TNF-α signaling pathway. This improved cardiac functional phenotypes, including cardiac diastolic dysfunction, pulmonary congestion, myocardial hypertrophy, reduced exercise tolerance, and glucose intolerance. AdipoRon improved heart rate variability (HRV) , decreased serum norepinephrine(NE), which inhibiting inflammation-induced cardiac sympathetic over-activation. AdipoRon dramatically reversed HFpEF-induced down-regulation of PI3K, Akt, and GSK3β phosphorylation, improved glucose metabolism and attenuated the cardiac damage associated with glucose accumulation. Our findings indicated AdipoRon’s ability to downregulate the expression of Bax/Bcl-2, inhibiting cardiomyocyte apoptosis, attenuating myocardial injury, and effectively improving cardiac function and ventricular remodeling. Conclusion: AdipoRon attenuated inflammatory response, improved cardiac function and phenotypes, and ameliorated impaired myocardial glucose metabolism and apoptosis in HFpEF mice. This was achieved by modulation of NLRP3/Caspase-1/IL-1β, Pl3K/Akt, and TLR4/NF-κB/TNF-α signaling pathways.

MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice

Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation

The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model

Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction.

The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence

Impeding Nucleotide‐Binding Oligomerization Domain‐Like Receptor 3 Inflammasome Ameliorates Cardiac Remodeling and Dysfunction in Obesity‐Associated Cardiomyopathy

MCC950 Ameliorates Ventricular Arrhythmia Vulnerability Induced by Heart Failure

The Selective NLRP3-inflammasome Inhibitor MCC950 Reduces Myocardial Fibrosis and Improves Cardiac Remodeling in a Mouse Model of Myocardial Infarction.

Cardiac-Specific Down-Regulation Of Carnitine Palmitoyltransferase-1b (Cpt-1b) Prevents Cardiac Remodeling In Obese Mice

Obesity enables NLRP3 activation and induces myocardial fibrosis via hyperacetylation of HADHa

LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway

Successful metabolic adaptations leading to the prevention of high fat diet-induced murine cardiac remodeling

Inhibition of Farnesyl Pyrophosphate Synthase Improves Pressure Overload Induced Chronic Cardiac Remodeling

Abstract 4142757: Adiponectin Receptor Agonist Alleviates Heart Failure with Preserved Ejection Fraction by Regulating NLRP3/Caspase-1/IL-1β and Pl3K/Akt Signaling Pathway

NLRP3-inflammasome Inhibition Prevents High Fat and High Sugar Diets-Induced Heart Damage Through Autophagy Induction.

MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis

LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice

Nlrp3 Inflammasome Inhibition By Mcc950 In Aged Mice Improves Health Via Enhanced Autophagy And Ppar Alpha Activity

Blunted Cardiac Mitophagy in Response to Metabolic Stress Contributes to HFpEF

Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF

SIRT3 Ablation Deteriorates Obesity-Related Cardiac Remodeling by Modulating ROS-NF-κB-MCP-1 Signaling Pathway.